Associated High Confidence AOPs |
---|
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:42 | Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | WPHA/WNT Endorsed | 0.12 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:54 | Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.1 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:110 | Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine System Disease | - | 0.14 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:112 | Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat) | Reproductive System Disease; Cancer | - | 0.17 | KE:111 | Agonism, Estrogen receptor |
AOP:119 | Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine System Disease | - | 0.14 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:122 | Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation | Unclassified | - | 0.1 | KE:799 | Increased, HIF-1 heterodimer |
AOP:134 | Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.11 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:136 | Intracellular Acidification Induced Olfactory Epithelial Injury Leading to Site of Contact Nasal Tumors | Benign Neoplasm; Respiratory System Disease | Under Review | 0.14 | KE:768 | Increase, Cytotoxicity |
AOP:159 | Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | 0.12 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:175 | Thyroperoxidase inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:176 | Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.2 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:192 | Pendrin inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:193 | Dual oxidase (DUOX) inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:207 | NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans | Reproductive System Disease | - | 0.12 | KE:1280 | Activation, HIF-1 |
AOP:232 | NFE2/Nrf2 repression to steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.12 | KE:1419 | Reduced, FXR activity |
AOP:263 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation | Unclassified | WPHA/WNT Endorsed | 0.25 | KE:1821 | Decrease, Cell proliferation |
AOP:267 | Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion | Unclassified | Under Development | 0.2 | KE:1821 | Decrease, Cell proliferation |
AOP:268 | Uncoupling of oxidative phosphorylation leading to growth inhibition via mitochondrial swelling | Unclassified | Under Development | 0.25 | KE:2072 | Increase, Mitochondrial swelling |
AOP:271 | Inhibition of thyroid peroxidase leading to impaired fertility in fish | Unclassified | Under Development | 0.2 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:286 | Mitochondrial complex III antagonism leading to growth inhibition (1) | Unclassified | - | 0.25 | KE:1821 | Decrease, Cell proliferation |
AOP:288 | Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals) | Endocrine System Disease | - | 0.12 | KE:1614 | Decrease, androgen receptor activation |
AOP:290 | Mitochondrial ATP synthase antagonism leading to growth inhibition (1) | Unclassified | - | 0.25 | KE:1821 | Decrease, Cell proliferation |
AOP:297 | Inhibition of retinaldehyde dehydrogenase leads to population decline | Unclassified | Under Development | 0.17 | KE:1643 | Altered, Visual function |
AOP:303 | Frustrated phagocytosis-induced lung cancer | Cancer | Under Development | 0.14 | KE:1669 | Increased, DNA damage and mutation |
AOP:305 | 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | 0.2 | KE:1614 | Decrease, androgen receptor activation |
AOP:327 | Excessive reactive oxygen species production leading to mortality (1) | Unclassified | - | 0.2 | KE:1769 | Increase, Body fluid overload |
AOP:328 | Excessive reactive oxygen species production leading to mortality (2) | Unclassified | - | 0.2 | KE:1770 | Decrease, Mitochondrial membrane potential |
AOP:331 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and reduced cell proliferation | Unclassified | - | 0.33 | KE:1821 | Decrease, Cell proliferation |
KE:1505 | Cell cycle, disrupted | |||||
AOP:332 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell proliferation | Unclassified | - | 0.4 | KE:1821 | Decrease, Cell proliferation |
KE:1505 | Cell cycle, disrupted | |||||
AOP:333 | Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation | Unclassified | - | 0.2 | KE:1821 | Decrease, Cell proliferation |
AOP:363 | Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure | Unclassified | Under Review | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:1643 | Altered, Visual function | |||||
AOP:364 | Thyroperoxidase inhibition leading to altered visual function via decreased eye size | Unclassified | Under Development | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:1643 | Altered, Visual function | |||||
AOP:365 | Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning | Unclassified | Under Development | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:1643 | Altered, Visual function | |||||
AOP:379 | Binding to ACE2 leading to thrombosis and disseminated intravascular coagulation | Cardiovascular System Disease | Under Development | 0.14 | KE:1845 | Coagulation |
AOP:387 | Deposition of ionising energy leading to population decline via mitochondrial dysfunction | Reproductive System Disease | - | 0.12 | KE:1770 | Decrease, Mitochondrial membrane potential |
AOP:399 | Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos) | Unclassified | - | 0.25 | KE:1821 | Decrease, Cell proliferation |
KE:1643 | Altered, Visual function | |||||
AOP:409 | Frustrated phagocytosis leads to malignant mesothelioma | Cancer | - | 0.12 | KE:1669 | Increased, DNA damage and mutation |
AOP:440 | Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia | Benign Neoplasm; Endocrine System Disease; Reproductive System Disease; Reproductive System Disease; Cancer; Endocrine System Disease | Under Development | 0.11 | KE:1973 | Increased, estrogens |
AOP:441 | Ionizing radiation-induced DNA damage leads to microcephaly via apoptosis and premature cell differentiation | Congenital Nervous System Abnormality; Nervous System Disease | - | 0.14 | KE:1974 | Activation of Tumor Protein 53 |
AOP:446 | PM-related Adverse outcome pathway frameworks on various systems | Respiratory System Disease | - | 0.1 | KE:18 | Activation, AhR |
KE:165 | Activation, Long term AHR receptor driven direct and indirect gene expression changes | |||||
AOP:449 | Ceramide synthase inhibition leading to neural tube defects | Neural Tube Defect | - | 0.14 | KE:1502 | Histone deacetylase inhibition |
AOP:451 | Interaction with lung resident cell membrane components leads to lung cancer | Cancer | - | 0.11 | KE:1669 | Increased, DNA damage and mutation |
AOP:452 | Adverse outcome pathway of PM-induced respiratory toxicity | Respiratory System Disease | - | 0.09 | KE:2013 | Airway remodeling |
AOP:457 | Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine | Inherited Metabolic Disorder | - | 0.17 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:460 | Antagonism of Smoothened receptor leading to orofacial clefting | Unclassified | Under Development | 0.11 | KE:1821 | Decrease, Cell proliferation |
AOP:465 | Alcohol dehydrogenase leading to reproductive dysfunction | Unclassified | - | 0.12 | KE:748 | Increased, Estrogen receptor (ER) activity |
AOP:491 | Decrease, GLI1/2 target gene expression leads to orofacial clefting | Unclassified | Under Development | 0.17 | KE:1821 | Decrease, Cell proliferation |
AOP:510 | Demethylation of PPAR promotor leading to vascular disrupting effects | Cardiovascular System Disease | - | 0.1 | KE:2165 | Activation of PPAR |
AOP:520 | Retinoic acid receptor agonism during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.2 | KE:2204 | Altered brain morphology |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:37 | PPARα activation leading to hepatocellular adenomas and carcinomas in rodents | Cancer; Gastrointestinal System Disease | Under Development | 0.4 | KE:719 | Increase, hepatocellular adenomas and carcinomas |
KE:716 | Increase, cell proliferation (hepatocytes) | |||||
AOP:43 | Disruption of VEGFR Signaling Leading to Developmental Defects | Unclassified | WPHA/WNT Endorsed | 0.2 | KE:1001 | Increased, Developmental Defects |
AOP:107 | Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat | Cancer; Gastrointestinal System Disease | Under Review | 0.6 | KE:719 | Increase, hepatocellular adenomas and carcinomas |
KE:1214 | Altered gene expression specific to CAR activation, Hepatocytes | |||||
KE:716 | Increase, cell proliferation (hepatocytes) | |||||
AOP:108 | Inhibition of pyruvate dehydrogenase kinase leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | - | 0.33 | KE:768 | Increase, Cytotoxicity |
KE:719 | Increase, hepatocellular adenomas and carcinomas | |||||
AOP:117 | Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | Under Development | 0.5 | KE:719 | Increase, hepatocellular adenomas and carcinomas |
KE:716 | Increase, cell proliferation (hepatocytes) | |||||
AOP:118 | Chronic cytotoxicity leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | - | 0.25 | KE:719 | Increase, hepatocellular adenomas and carcinomas |
AOP:139 | Alkylation of DNA leading to cancer 1 | Cancer | - | 0.25 | KE:885 | Increase, Cancer |
AOP:220 | Cyp2E1 Activation Leading to Liver Cancer | Cancer; Gastrointestinal System Disease | WPHA/WNT Endorsed | 0.2 | KE:1395 | Liver Cancer |
AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal System Disease | - | 0.09 | KE:2034 | liver dysfunction |
AOP:474 | Succinate dehydrogenase inactivation leads to cancer by promoting EMT | Cancer | Under Development | 0.2 | KE:885 | Increase, Cancer |
AOP:504 | SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level | Unclassified | - | 0.33 | KE:1065 | Activation, estrogen receptor alpha |
AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | 0.2 | KE:885 | Increase, Cancer |
AOP:513 | Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway | Cancer | - | 0.2 | KE:885 | Increase, Cancer |
AOP:534 | Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress | Cancer | - | 0.17 | KE:885 | Increase, Cancer |
AOP:546 | Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms | Cancer | - | 0.2 | KE:885 | Increase, Cancer |
AOP:561 | Aromatase induction leading to estrogen receptor alpha activation via increased estradiol | Unclassified | - | 0.2 | KE:1065 | Activation, estrogen receptor alpha |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:19 | Androgen receptor antagonism leading to adverse effects in the male foetus (mammals) | Reproductive System Disease | - | 0.2 | KE:26 | Antagonism, Androgen receptor |
AOP:21 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 | Unclassified | WPHA/WNT Endorsed | 0.2 | KE:18 | Activation, AhR |
AOP:41 | Sustained AhR Activation leading to Rodent Liver Tumours | Cancer; Gastrointestinal System Disease | Under Review | 0.2 | KE:165 | Activation, Long term AHR receptor driven direct and indirect gene expression changes |
AOP:111 | Decrease in androgen receptor activity leading to Leydig cell tumors (in rat) | Cancer; Reproductive System Disease | - | 0.2 | KE:1614 | Decrease, androgen receptor activation |
AOP:123 | Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription | Unclassified | - | 0.27 | KE:799 | Increased, HIF-1 heterodimer |
KE:801 | modulation, Unknown | |||||
KE:802 | Increased, HIF-1 alpha transcription | |||||
AOP:128 | Kidney dysfunction by decreased thyroid hormone | Urinary System Disease | Under Development | 0.09 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:131 | Aryl hydrocarbon receptor activation leading to uroporphyria | Inherited Metabolic Disorder | WPHA/WNT Endorsed | 0.33 | KE:18 | Activation, AhR |
KE:850 | Induction, CYP1A2/CYP1A5 | |||||
AOP:150 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF | Unclassified | WPHA/WNT Endorsed | 0.14 | KE:18 | Activation, AhR |
AOP:151 | AhR activation leading to preeclampsia | Cardiovascular System Disease | Under Development | 0.14 | KE:18 | Activation, AhR |
AOP:155 | Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | 0.17 | KE:1002 | Inhibition, Deiodinase 2 |
AOP:156 | Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | 0.17 | KE:1002 | Inhibition, Deiodinase 2 |
AOP:167 | Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. | Reproductive System Disease; Cancer | - | 0.29 | KE:1064 | prepubertal increase, Estrogen receptor (ER) activity |
KE:1065 | Activation, estrogen receptor alpha | |||||
AOP:188 | Iodotyrosine deiodinase (IYD) inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.4 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:1152 | Inhibition, Iodotyrosine deiodinase (IYD) | |||||
AOP:190 | Type II iodothyronine deiodinase (DIO2) inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.17 | KE:1002 | Inhibition, Deiodinase 2 |
AOP:191 | Type III iodotyrosine deiodinase (DIO3) inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.25 | KE:1153 | Inhibition, Deiodinase 3 |
AOP:212 | Histone deacetylase inhibition leading to testicular atrophy | Reproductive System Disease | WPHA/WNT Endorsed | 0.33 | KE:1502 | Histone deacetylase inhibition |
KE:1505 | Cell cycle, disrupted | |||||
AOP:269 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired growth and development | Unclassified | - | 0.17 | KE:10008 | Increased transcription for detoxification and repair mechanism |
AOP:270 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired locomotor activity | Unclassified | - | 0.12 | KE:10008 | Increased transcription for detoxification and repair mechanism |
AOP:275 | Histone deacetylase inhibition leads to neural tube defects | Neural Tube Defect | - | 0.2 | KE:1502 | Histone deacetylase inhibition |
AOP:306 | Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | 0.5 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor | |||||
AOP:310 | Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR | Unclassified | - | 0.08 | KE:18 | Activation, AhR |
AOP:314 | Binding to estrogen receptor (ER)-α in immune cells leading to exacerbation of systemic lupus erythematosus (SLE) | Immune System Disease; Musculoskeletal System Disease | Under Development | 0.2 | KE:1710 | Binding to estrogen receptor (ER)-α in immune cells |
AOP:344 | Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring | Unclassified | Under Development | 0.5 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor | |||||
AOP:345 | Androgen receptor (AR) antagonism leading to decreased fertility in females | Endocrine System Disease; Reproductive System Disease; Reproductive System Disease | Under Development | 0.33 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor | |||||
AOP:372 | Androgen receptor antagonism leading to testicular cancer | Endocrine System Disease; Reproductive System Disease; Cancer | - | 0.4 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor | |||||
AOP:414 | Aryl hydrocarbon receptor activation leading to lung fibrosis through TGF-β dependent fibrosis toxicity pathway | Musculoskeletal System Disease; Respiratory System Disease | - | 0.2 | KE:18 | Activation, AhR |
AOP:415 | Aryl hydrocarbon receptor activation leading to lung fibrosis through IL-6 toxicity pathway | Musculoskeletal System Disease; Respiratory System Disease | - | 0.2 | KE:18 | Activation, AhR |
AOP:416 | Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway | Cancer | - | 0.33 | KE:18 | Activation, AhR |
KE:1669 | Increased, DNA damage and mutation | |||||
AOP:417 | Aryl hydrocarbon receptor activation leading to lung cancer through AHR-ARNT toxicity pathway | Cancer | - | 0.4 | KE:18 | Activation, AhR |
KE:1669 | Increased, DNA damage and mutation | |||||
AOP:418 | Aryl hydrocarbon receptor activation leading to impaired lung function through AHR-ARNT toxicity pathway | Respiratory System Disease | - | 0.2 | KE:18 | Activation, AhR |
AOP:419 | Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathway | Respiratory System Disease | - | 0.5 | KE:18 | Activation, AhR |
KE:1923 | Altered gene expression, P53 dependent apoptosis pathway | |||||
AOP:420 | Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathway | Cancer | - | 0.5 | KE:18 | Activation, AhR |
KE:1917 | Altered gene expression, NRF2 dependent antioxidant pathway | |||||
AOP:439 | Activation of the AhR leading to metastatic breast cancer | Thoracic Disease; Cancer | Under Development | 0.22 | KE:18 | Activation, AhR |
KE:1971 | Increased, tumor growth | |||||
AOP:443 | DNA damage and mutations leading to Metastatic Breast Cancer | Thoracic Disease; Cancer | Under Development | 0.2 | KE:1669 | Increased, DNA damage and mutation |
KE:1554 | Increase Chromosomal Aberrations | |||||
AOP:445 | Estrogen Receptor Alpha Agonism leads to Impaired Reproduction | Reproductive System Disease | - | 0.12 | KE:1065 | Activation, estrogen receptor alpha |
AOP:447 | Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways | Urinary System Disease | - | 0.17 | KE:1917 | Altered gene expression, NRF2 dependent antioxidant pathway |
KE:1770 | Decrease, Mitochondrial membrane potential | |||||
AOP:456 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity | Unclassified | Under Review | 0.17 | KE:18 | Activation, AhR |
AOP:458 | AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.12 | KE:18 | Activation, AhR |
AOP:459 | AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.33 | KE:18 | Activation, AhR |
KE:277 | Thyroid hormone synthesis, Decreased | |||||
KE:850 | Induction, CYP1A2/CYP1A5 | |||||
AOP:477 | Androgen receptor (AR) antagonism leading to hypospadias in male (mammalian) offspring | Physical Disorder | - | 0.67 | KE:1614 | Decrease, androgen receptor activation |
KE:26 | Antagonism, Androgen receptor | |||||
AOP:493 | ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity | Acquired Metabolic Disease | - | 0.1 | KE:2126 | Estrogen receptor alpha inactivation |
AOP:494 | AhR activation leading to liver fibrosis | Gastrointestinal System Disease | - | 0.17 | KE:18 | Activation, AhR |
AOP:497 | ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome | Inherited Metabolic Disorder; Disease Of Metabolism | - | 0.12 | KE:2126 | Estrogen receptor alpha inactivation |
AOP:503 | Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation | Reproductive System Disease; Cancer | Under Review | 0.17 | KE:1065 | Activation, estrogen receptor alpha |
AOP:536 | Estrogen receptor agonism leading to reduced survival and population growth due to renal failure | Unclassified | - | 0.17 | KE:111 | Agonism, Estrogen receptor |
AOP:537 | Estrogen receptor agonism leads to reduced fecundity via increased vitellogenin in the liver | Unclassified | - | 0.2 | KE:111 | Agonism, Estrogen receptor |
AOP:563 | Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis | Reproductive System Disease; Endocrine System Disease | - | 0.17 | KE:18 | Activation, AhR |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:274 | Histone deacetylase inhibition leads to impeded craniofacial development | Musculoskeletal System Disease | - | 0.5 | KE:1559 | Facial cartilage structures are reduced in size and morphologically distorted |
KE:1502 | Histone deacetylase inhibition | |||||
AOP:455 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial development | Musculoskeletal System Disease | Under Review | 0.33 | KE:18 | Activation, AhR |
KE:1559 | Facial cartilage structures are reduced in size and morphologically distorted |
TICToK is a database of tattoo ink chemicals compiled from different regulatory resources. The authors are not liable for any inaccuracies or omissions of any chemicals in this resource. Importantly, our sole goal to build this resource on tattoo ink chemicals is to enable future basic research on this topic, and it does not necessarily reflect the views or objectives of our employers or funders.